Mergers & Acquisitions ·
Exicure agrees to sell GPC-100 program assets for KRW 6.5 billion (US$4.8 million)
XCURExicure, Inc.
Exicure, Inc. and its subsidiary GPCR Therapeutics USA have entered into an agreement with South Korean firm GPCRT Inc. to sell the rights and assets related to the GPC-100 (burixafor) program for KRW 6.5 billion (approximately US$4.8 million). The transaction includes a previously paid deposit of KRW 500 million, an interim payment of KRW 2.0 billion due by November 16, 2026, and a final payment at closing. GPCRT will assume future milestone obligations and program costs incurred after September 1, 2026. The deal is subject to customary closing conditions, including regulatory approvals and third-party consents. Exicure operates as an early-stage biotechnology company focused on nucleic acid therapies.